{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:51:12Z","timestamp":1789411872335,"version":"build-2803163510"},"reference-count":76,"publisher":"The Company of Biologists","issue":"3-4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2,25]]},"abstract":"<jats:p>An accepted prerequisite for clinical trials of a compound in humans is the successful alleviation of the disease in animal models. For some diseases, however, successful translation of drug effects from mouse models to the bedside has been limited. One question is whether the current models accurately reproduce the human disease. Here, we examine the mouse models that are available for therapeutic testing in Huntington disease (HD), a late-onset neurodegenerative disorder for which there is no effective treatment. The current mouse models show different degrees of similarity to the human condition. Significant phenotypic differences are seen in mouse models that express either truncated or full-length human, or full-length mouse, mutant huntingtin (mHTT). These differences in phenotypic expression may be attributable to the influences of protein context, mouse strain and a difference in regulatory sequences between the mouse Htt and human HTT genes.<\/jats:p>","DOI":"10.1242\/dmm.002451","type":"journal-article","created":{"date-parts":[[2009,2,26]],"date-time":"2009-02-26T19:48:30Z","timestamp":1235677710000},"page":"123-129","source":"Crossref","is-referenced-by-count":90,"title":["Mouse models of Huntington disease: variations on a theme"],"prefix":"10.1242","volume":"2","author":[{"given":"Dagmar E.","family":"Ehrnhoefer","sequence":"first","affiliation":[{"name":"Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, Child and Family Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie L.","family":"Butland","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, Child and Family Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.","family":"Pouladi","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, Child and Family Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, Child and Family Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"237","reference":[{"key":"2021042501111889700_b1-0020123","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJM199005033221807","article-title":"Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington\u2019s disease","volume":"322","author":"Albin","year":"1990","journal-title":"N. Engl. J. Med"},{"key":"2021042501111889700_b2-0020123","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature07242","article-title":"The impact of microRNAs on protein output","volume":"455","author":"Baek","year":"2008","journal-title":"Nature"},{"key":"2021042501111889700_b3-0020123","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0692-180","article-title":"Characterization of a yeast artificial chromosome contig spanning the Huntington\u2019s disease gene candidate region","volume":"1","author":"Bates","year":"1992","journal-title":"Nat. Genet"},{"key":"2021042501111889700_b4-0020123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2006.12.015","article-title":"Lost in translation: treatment trials in the SOD1 mouse and in human ALS","volume":"26","author":"Benatar","year":"2007","journal-title":"Neurobiol. Dis"},{"key":"2021042501111889700_b5-0020123","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0169-328X(95)00124-B","article-title":"The identification of a functional nuclear localization signal in the Huntington disease protein","volume":"33","author":"Bessert","year":"1995","journal-title":"Brain Res. Mol. Brain Res"},{"key":"2021042501111889700_b6-0020123","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1523\/JNEUROSCI.16-17-05523.1996","article-title":"Expression of normal and mutant huntingtin in the developing brain","volume":"16","author":"Bhide","year":"1996","journal-title":"J. Neurosci"},{"key":"2021042501111889700_b7-0020123","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/hmg\/6.11.1951","article-title":"Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice","volume":"6","author":"Carlson","year":"1997","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b8-0020123","doi-asserted-by":"crossref","first-page":"23950","DOI":"10.1074\/jbc.M800467200","article-title":"A common motif targets huntingtin and the androgen receptor to the proteasome","volume":"283","author":"Chandra","year":"2008","journal-title":"J. Biol. Chem"},{"key":"2021042501111889700_b9-0020123","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.20903","article-title":"Trial of celecoxib in amyotrophic lateral sclerosis","volume":"60","author":"Cudkowicz","year":"2006","journal-title":"Ann. Neurol"},{"key":"2021042501111889700_b10-0020123","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"2021042501111889700_b11-0020123","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.10374","article-title":"Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS","volume":"52","author":"Drachman","year":"2002","journal-title":"Ann. Neurol"},{"key":"2021042501111889700_b12-0020123","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1523\/JNEUROSCI.17-09-03052.1997","article-title":"Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum","volume":"17","author":"Ferrante","year":"1997","journal-title":"J. Neurosci"},{"key":"2021042501111889700_b13-0020123","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington\u2019s disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci"},{"key":"2021042501111889700_b14-0020123","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1523\/JNEUROSCI.22-12-04842.2002","article-title":"Calpain activation in Huntington\u2019s disease","volume":"22","author":"Gafni","year":"2002","journal-title":"J. Neurosci"},{"key":"2021042501111889700_b15-0020123","doi-asserted-by":"crossref","first-page":"20211","DOI":"10.1074\/jbc.M401267200","article-title":"Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain\/caspase fragments in the nucleus","volume":"279","author":"Gafni","year":"2004","journal-title":"J. Biol. Chem"},{"key":"2021042501111889700_b16-0020123","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","article-title":"Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial","volume":"6","author":"Gordon","year":"2007","journal-title":"Lancet Neurol"},{"key":"2021042501111889700_b17-0020123","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","article-title":"Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin","volume":"125","author":"Graham","year":"2006","journal-title":"Cell"},{"key":"2021042501111889700_b18-0020123","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","article-title":"Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice","volume":"28","author":"Gray","year":"2008","journal-title":"J. Neurosci"},{"key":"2021042501111889700_b19-0020123","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molcel.2007.06.017","article-title":"MicroRNA targeting specificity in mammals: determinants beyond seed pairing","volume":"27","author":"Grimson","year":"2007","journal-title":"Mol. Cell"},{"key":"2021042501111889700_b20-0020123","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ana.10554","article-title":"A randomized sequential trial of creatine in amyotrophic lateral sclerosis","volume":"53","author":"Groeneveld","year":"2003","journal-title":"Ann. Neurol"},{"key":"2021042501111889700_b21-0020123","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1126\/science.8209258","article-title":"Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation","volume":"264","author":"Gurney","year":"1994","journal-title":"Science"},{"key":"2021042501111889700_b22-0020123","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1523\/JNEUROSCI.1830-07.2007","article-title":"Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington\u2019s disease","volume":"27","author":"Heng","year":"2007","journal-title":"J. Neurosci"},{"key":"2021042501111889700_b23-0020123","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.cdd.4401358","article-title":"Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington\u2019s disease","volume":"11","author":"Hermel","year":"2004","journal-title":"Cell Death Differ"},{"key":"2021042501111889700_b24-0020123","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/hmg\/5.12.1875","article-title":"Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype","volume":"5","author":"Hodgson","year":"1996","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b25-0020123","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","article-title":"A YAC mouse model for Huntington\u2019s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration","volume":"23","author":"Hodgson","year":"1999","journal-title":"Neuron"},{"key":"2021042501111889700_b26-0020123","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1523\/JNEUROSCI.3356-04.2004","article-title":"Caspase-7 expanded function and intrinsic expression level underlies strain-specific brain phenotype of caspase-3-null mice","volume":"24","author":"Houde","year":"2004","journal-title":"J. Neurosci"},{"key":"2021042501111889700_b27-0020123","doi-asserted-by":"crossref","first-page":"D610","DOI":"10.1093\/nar\/gkl996","article-title":"Ensembl 2007","volume":"35","author":"Hubbard","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"2021042501111889700_b28-0020123","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease","volume":"57","author":"Huntington Study Group","year":"2001","journal-title":"Neurology"},{"key":"2021042501111889700_b29-0020123","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"Huntington Study Group","year":"2006","journal-title":"Neurology"},{"key":"2021042501111889700_b30-0020123","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.nbd.2007.11.001","article-title":"A microRNA-based gene dysregulation pathway in Huntington\u2019s disease","volume":"29","author":"Johnson","year":"2008","journal-title":"Neurobiol. Dis"},{"key":"2021042501111889700_b31-0020123","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1101\/gr.229102","article-title":"The human genome browser at UCSC","volume":"12","author":"Kent","year":"2002","journal-title":"Genome Res"},{"key":"2021042501111889700_b32-0020123","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1140481","article-title":"A MicroRNA feedback circuit in midbrain dopamine neurons","volume":"317","author":"Kim","year":"2007","journal-title":"Science"},{"key":"2021042501111889700_b33-0020123","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/6568","article-title":"Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis","volume":"5","author":"Klivenyi","year":"1999","journal-title":"Nat. Med"},{"key":"2021042501111889700_b34-0020123","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington\u2019s disease: a 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann. Neurol"},{"key":"2021042501111889700_b35-0020123","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/nn.2183","article-title":"miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis","volume":"11","author":"Lee","year":"2008","journal-title":"Nat. Neurosci"},{"key":"2021042501111889700_b36-0020123","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neuroimage.2008.02.019","article-title":"Cortical thickness measured from MRI in the YAC128 mouse model of Huntington\u2019s disease","volume":"41","author":"Lerch","year":"2008","journal-title":"Neuroimage"},{"key":"2021042501111889700_b37-0020123","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0092-8674(03)01018-3","article-title":"Prediction of mammalian microRNA targets","volume":"115","author":"Lewis","year":"2003","journal-title":"Cell"},{"key":"2021042501111889700_b38-0020123","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/hmg\/2.10.1541","article-title":"Differential 3\u2032 polyadenylation of the Huntington disease gene results in two mRNA species with variable tissue expression","volume":"2","author":"Lin","year":"1993","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b39-0020123","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/hmg\/3.1.85","article-title":"Sequence of the murine Huntington disease gene: evidence for conservation, alternate splicing and polymorphism in a triplet (CCG) repeat [corrected]","volume":"3","author":"Lin","year":"1994","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b40-0020123","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/hmg\/10.2.137","article-title":"Neurological abnormalities in a knock-in mouse model of Huntington\u2019s disease","volume":"10","author":"Lin","year":"2001","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b41-0020123","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1097-2765(02)00602-0","article-title":"Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions","volume":"10","author":"Lunkes","year":"2002","journal-title":"Mol. Cell"},{"key":"2021042501111889700_b42-0020123","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"2021042501111889700_b43-0020123","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1093\/hmg\/ddn201","article-title":"A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex","volume":"17","author":"Mellios","year":"2008","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b44-0020123","doi-asserted-by":"crossref","first-page":"8266","DOI":"10.1523\/JNEUROSCI.22-18-08266.2002","article-title":"Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington\u2019s disease knock-in mice","volume":"22","author":"Menalled","year":"2002","journal-title":"J. Neurosci"},{"key":"2021042501111889700_b45-0020123","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington\u2019s disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J. Comp. Neurol"},{"key":"2021042501111889700_b46-0020123","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/14660820310002601","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"4","author":"Miller","year":"2003","journal-title":"Amyotroph. Lateral Scler. Other Motor Neuron Disord"},{"key":"2021042501111889700_b47-0020123","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/B978-012369462-1\/50016-8","article-title":"Molecular pathogenesis of Huntington\u2019s disease: the role of excitotoxicity","volume-title":"Genetic Instabilities and Neurological Diseases","author":"Pouladi","year":"2006"},{"key":"2021042501111889700_b48-0020123","article-title":"Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin","author":"Pouladi","year":"2009","journal-title":"Brain"},{"key":"2021042501111889700_b49-0020123","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","article-title":"Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial","volume":"65","author":"Puri","year":"2005","journal-title":"Neurology"},{"key":"2021042501111889700_b50-0020123","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.brainres.2005.01.067","article-title":"Susceptibility to excitotoxic and metabolic striatal neurodegeneration in the mouse is genotype dependent","volume":"1040","author":"Schauwecker","year":"2005","journal-title":"Brain Res"},{"key":"2021042501111889700_b51-0020123","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/mds.10229","article-title":"Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington\u2019s disease","volume":"17","author":"Schiefer","year":"2002","journal-title":"Mov. Disord"},{"key":"2021042501111889700_b52-0020123","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","article-title":"Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin","volume":"8","author":"Schilling","year":"1999","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b53-0020123","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","article-title":"Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington\u2019s disease transgenic mouse model","volume":"315","author":"Schilling","year":"2001","journal-title":"Neurosci. Lett"},{"key":"2021042501111889700_b54-0020123","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/0959-4388(95)80060-3","article-title":"Silencing is golden: negative regulation in the control of neuronal gene transcription","volume":"5","author":"Schoenherr","year":"1995","journal-title":"Curr. Opin. Neurobiol"},{"key":"2021042501111889700_b55-0020123","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1212\/01.WNL.0000142992.81995.F0","article-title":"A clinical trial of creatine in ALS","volume":"63","author":"Shefner","year":"2004","journal-title":"Neurology"},{"key":"2021042501111889700_b56-0020123","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/hmg\/8.5.763","article-title":"A Huntington\u2019s disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice","volume":"8","author":"Shelbourne","year":"1999","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b57-0020123","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b58-0020123","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1126\/science.1092194","article-title":"SUMO modification of Huntingtin and Huntington\u2019s disease pathology","volume":"304","author":"Steffan","year":"2004","journal-title":"Science"},{"key":"2021042501111889700_b59-0020123","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1523\/JNEUROSCI.1396-07.2007","article-title":"Dopaminergic signaling and striatal neurodegeneration in Huntington\u2019s disease","volume":"27","author":"Tang","year":"2007","journal-title":"J. Neurosci"},{"key":"2021042501111889700_b60-0020123","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"2021042501111889700_b61-0020123","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.brainresbull.2006.10.023","article-title":"Predictive testing for Huntington\u2019s disease","volume":"72","author":"Tibben","year":"2007","journal-title":"Brain Res. Bull"},{"key":"2021042501111889700_b62-0020123","doi-asserted-by":"crossref","first-page":"20775","DOI":"10.1074\/jbc.M313873200","article-title":"On the sequential determinants of calpain cleavage","volume":"279","author":"Tompa","year":"2004","journal-title":"J. Biol. Chem"},{"key":"2021042501111889700_b63-0020123","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1139\/o06-181","article-title":"Hypothesis: Huntingtin may function in membrane association and vesicular trafficking","volume":"84","author":"Truant","year":"2006","journal-title":"Biochem. Cell Biol"},{"key":"2021042501111889700_b64-0020123","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1093\/hmg\/ddi407","article-title":"Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease","volume":"14","author":"Van Raamsdonk","year":"2005","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b65-0020123","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1523\/JNEUROSCI.0590-05.2005","volume":"25","author":"Van Raamsdonk","year":"2005","journal-title":"J. Neurosci"},{"key":"2021042501111889700_b66-0020123","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1471-4159.2005.03357.x","article-title":"Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease","volume":"95","author":"Van Raamsdonk","year":"2005","journal-title":"J. Neurochem"},{"key":"2021042501111889700_b67-0020123","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.expneurol.2005.07.021","article-title":"Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease","volume":"196","author":"Van Raamsdonk","year":"2005","journal-title":"Exp. Neurol"},{"key":"2021042501111889700_b68-0020123","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.drudis.2007.10.011","article-title":"Strategic approaches to developing drug treatments for ALS","volume":"13","author":"Vincent","year":"2008","journal-title":"Drug Discov. Today"},{"key":"2021042501111889700_b69-0020123","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/hmg\/ddi165","article-title":"Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo","volume":"14","author":"Warby","year":"2005","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b70-0020123","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1093\/hmg\/ddn139","article-title":"Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus","volume":"17","author":"Warby","year":"2008","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b71-0020123","doi-asserted-by":"crossref","first-page":"19831","DOI":"10.1074\/jbc.M001475200","article-title":"Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells","volume":"275","author":"Wellington","year":"2000","journal-title":"J. Biol. Chem"},{"key":"2021042501111889700_b72-0020123","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/9.4.503","article-title":"Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice","volume":"9","author":"Wheeler","year":"2000","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b73-0020123","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/hmg\/ddg156","article-title":"Huntingtin contains a highly conserved nuclear export signal","volume":"12","author":"Xia","year":"2003","journal-title":"Hum. Mol. Genet"},{"key":"2021042501111889700_b74-0020123","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nn1702","article-title":"Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function","volume":"9","author":"Yanai","year":"2006","journal-title":"Nat. Neurosci"},{"key":"2021042501111889700_b75-0020123","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/sj.cdd.4400593","article-title":"Caspase knockouts: matters of life and death","volume":"6","author":"Zheng","year":"1999","journal-title":"Cell Death Differ"},{"key":"2021042501111889700_b76-0020123","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/417074a","article-title":"Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice","volume":"417","author":"Zhu","year":"2002","journal-title":"Nature"}],"container-title":["Disease Models &amp; Mechanisms"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.biologists.com\/dmm\/article-pdf\/2\/3-4\/123\/1616207\/123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/journals.biologists.com\/dmm\/article-pdf\/2\/3-4\/123\/1616207\/123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T01:12:12Z","timestamp":1619313132000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.biologists.com\/dmm\/article\/2\/3-4\/123\/3473\/Mouse-models-of-Huntington-disease-variations-on-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,25]]},"references-count":76,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2009,2,25]]}},"URL":"https:\/\/doi.org\/10.1242\/dmm.002451","relation":{},"ISSN":["1754-8411","1754-8403"],"issn-type":[{"value":"1754-8411","type":"electronic"},{"value":"1754-8403","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2,25]]}}}